Phase I safety/tolerability, immunological and clinical
study of Affitope AD02 is ongoing (See NCT01093664).
A Phase II interventional trial has been announced but is
not yet open for participant recruitment, and will be
located at approximately 30 study sites in Europe. (See NCT01117818).
This record was updated September 29, 2010.